Use of Rivaroxaban for Prevention of Venous Thromboembolic Complications in Elderly Patients after Hip Arthroplasty

A. P Afanas’ev; A. A Kardanov; A. S Karandin; A. V Korolev

doi:10.17816/vto201623374-77

N.N. Priorov Journal of Traumatology and Orthopedics ›› 2016, Vol. 23 ›› Issue (3) : 74 -77. DOI: 10.17816/vto201623374-77

Short communications

brief-report

Use of Rivaroxaban for Prevention of Venous Thromboembolic Complications in Elderly Patients after Hip Arthroplasty

Author information +

History +

PDF

Abstract

Results of retrospective analysis of the efficacy and safety of venous thromboembolic complications prevention using anticoagulants (low-molecular-weight heparins and rivaroxaban) in elderly (over 75 years) patients after hip arthroplasty are presented. Ninety four patients were divided into 2 groups (n=47) depending on the applied anticoagulant. Follow up period was 6 months after hospitalization. Asymptomatic thrombosis was diagnosed by duplex ultrasonography only in 1 (2.1%) patient from low-molecular-weight heparin group. No one case of either bleeding or hemorrhage was recorded. It is stated that rivaroxaban ensured effective thromboprophylaxis and safety after hip arthroplasty in elderly patients when no restrictions related to the use of low-molecular-weight heparin injections are present.

Keywords

hip arthroplasty / venous thromboembolic complications prevention / bleeding / hemorrhage / rivaroxaban

Cite this article

Download citation ▾

A. P Afanas’ev, A. A Kardanov, A. S Karandin, A. V Korolev. Use of Rivaroxaban for Prevention of Venous Thromboembolic Complications in Elderly Patients after Hip Arthroplasty. N.N. Priorov Journal of Traumatology and Orthopedics, 2016, 23(3): 74-77 DOI:10.17816/vto201623374-77

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372 (9632): 31-9.

[2]	Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008; 358 (26): 2776-86.

[3]	Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galiè N., Pruszczyk P. et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J. 2008; 29 (18): 2276-2315.

[4]	Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., Colwell C.W. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest J. 2008; 133 (6_suppl.): 381S-453S.

[5]	Haines S.T. Improving anticoagulant use for prevention of venous thromboembolism. Am. J. Health. Syst. Pharm. 2010; 67 (10 Suppl 6): S2-3.

[6]	Huddleston J.I., Wang Y., Uquillas C., Herndon J.H., Maloney W.J. Age and obesity are risk factors for adverse events after total hip arthroplasty. Clin. Orthop. Relat. Res. 2012; 470 (2): 490-6.

[7]	Lichte P., Kobbe P., Almahmoud K., Pfeifer R., Andruszkow H., Hildebrand F. et al. Post-traumatic thromboembolic complications in polytrauma patients. Int. Orthop. 2015; 39 (5): 947-54.

[8]	Явелов И.С. Антикоагулянты для профилактики венозных тромбоэмболических осложнений у хирургических больных: особенности применения на практике. Клиническая патофизиология. 2013; 4: 34-43.

[9]	Coventry M.B., Nolan D.R., Beckenbaugh R.D. “Delayed” prophylactic anticoagulation: A study of results and complications in 2,012 total hip arthroplasties. J. Bone Joint Surg. Am. 1973; 55 (7): 1487-92.

[10]	Enyart J.J., Jones R.J. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann. Pharmacother. 2005; 39 (6): 1002-7.

[11]	Fitzgerald R.H., Spiro T.E., Trowbridge A.A., Gardiner G.A. Jr, Whitsett T.L., O'Connell M.B. et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J. Bone Joint Surg. Am. 2001; 83 (6): 900-6.

[12]	Cook L.M., Kahn S.R., Goodwin J., Kovacs M.J. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J. Thromb. Haemost. 2007; 5 (5): 937-41.

[13]	Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., Cushner F.D., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373 (9676): 1673-80.

[14]	Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz S.D., Misselwitz F., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 2011; 105 (3): 444-53.

[15]	Tan L., Qi B., Yu T., Wang C. Incidence and risk factors for venous thromboembolism following surgical treatment of fractures below the hip: a meta-analysis. Int. Wound J. 2016.